EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
نویسنده
چکیده
EUROmediCAT Steering Group: Helen Dolk (Ulster University, United Kingdom), Lolkje de Jong-van den Berg (Groningen University, The Netherlands), Anna Pierini (Institute of Clinical Pysiology-National Research Council, Pisa, Italy), Joan Morris (Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom), Marian Bakker (University Medical Center Groning, The Netherlands), Sue Jordan (Swansea University, United Kingdon), Ester Garne (Hospital Lillebaelt, Denmark), Kari Klungsoyr (University of Bergen, Norway), Maria Loane (Ulster University, United Kingdom), Rachel Charlton (University of Bath, United Kingdom), Michiel Luteijn (Ulster University, United Kingdom), Marlene Sinclair (Ulster University, United Kingdom), Anna Latos Bielenska (Poznan University of Medical Sciences, Poland).
منابع مشابه
Medication Errors Associated With Adverse Drug Reactions in Iran (2015-2017): A P-Method Approach
Medication errors are the second most common cause of adverse patient safety incidents and the single most common preventable cause of adverse events in medical practice. Given the high human fatalities and financial burden of medication errors for healthcare systems worldwide, reducing their occurrence is a global priority. Therefore, appropriate policies to reduce medication errors, using nat...
متن کاملThe Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project
The Monitoring Medicines project (MM), funded by the FP-7 EU framework, was carried out between 2009 and 2013 by a consortium of 11 partners. The objectives were to support and strengthen consumer reporting of adverse drug reactions (ADRs); expand the role and scope of national pharmacovigilance centres concerning medication errors; promote improved use of pharmacovigilance data; and develop me...
متن کاملMedication exposure during pregnancy: a pilot pharmacovigilance system using health and demographic surveillance platform
BACKGROUND There is limited safety information on most drugs used during pregnancy. This is especially true for medication against tropical diseases because pharmacovigilance systems are not much developed in these settings. The aim of the present study was to demonstrate feasibility of using Health and Demographic Surveillance System (HDSS) as a platform to monitor drug safety in pregnancy. ...
متن کاملSafety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.
When contemplating a pregnancy, women treated for multiple sclerosis (MS) with a disease-modifying drug must decide to discontinue their medication before conception or risk exposing their unborn child to potential drug toxicity. Few studies exist as reference for patients and physicians, and of those available, the majority are less than ideal due to real-world constraints, ethical issues and ...
متن کاملImproving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study
INTRODUCTION Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of ob...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Pharmacoepidemiology and drug safety
دوره 24 Suppl 2 شماره
صفحات -
تاریخ انتشار 2015